1. Home
  2. Products
  3. Customized ADCs
  4. ANGPTL3
  5. Anti-ANGPTL3-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC

Anti-ANGPTL3-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2329)

This ADC product is comprised of an anti-ANGPTL3 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • ANGPTL3
  • Alternative Names
  • ANGPTL3; angiopoietin-like 3; ANGPT5; angiopoietin-related protein 3; angiopoietin 5; ANG-5; FHBL2;
  • Target Entrez Gene ID
  • 27329
  • Overview
  • This gene encodes a member of a family of secreted proteins that function in angiogenesis. The encoded protein, which is expressed predominantly in the liver, is further processed into an N-terminal coiled-coil domain-containing chain and a C-terminal fibrinogen chain. The N-terminal chain is important for lipid metabolism, while the C-terminal chain may be involved in angiogenesis. Mutations in this gene cause familial hypobetalipoproteinemia type 2.
  • Overview
  • Human Anti-ANGPTL3 IgG antibody
  • Generic name
  • Anti-Human ANGPTL3 Therapeutic Antibody
  • Host animal
  • Human
  • Name
  • MC-Vc-PAB-DMEA-(PEG2)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • duocarmycin SA
  • Description
  • Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-2329. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2326 Anti-ANGPTL3-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2328 Anti-ANGPTL3-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2327 Anti-ANGPTL3-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-2325 Anti-ANGPTL3-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2324 Anti-ANGPTL3-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-2615 Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2619 Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2553 Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2547 Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2576 Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
CAT# Product Name Linker Payload
ADC-W-2576 Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2615 Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2547 Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2542 Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2588 Anti-EGFR (Zalutumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.